The Eon Mini Neurostimulation (IPG) System (Model 3788) is a 16-channel, rechargeable, multi-prog...
FDA Device Recall #Z-2281-2012 - Class II, December 19, 2011
Recall Summary
| Recall Number | Z-2281-2012 |
| Classification | Class II - Moderate risk |
| Date Initiated | December 19, 2011 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Advanced Neuromodulation Systems Inc. |
| Location | Plano, TX |
| Product Type | Devices |
| Quantity | 30,560 units |
Product Description
The Eon Mini Neurostimulation (IPG) System (Model 3788) is a 16-channel, rechargeable, multi-program system that allows the connection of one or two leads with 4, 8, and 16 electrode leads. Product Usage: The Eon and Eon Mini Neurostimulation Systems are indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back and leg pain.
Reason for Recall
As of 11/30/2011, St. Jude Medical has received 110 patient complaints of warmth or heating at the implantable pulse generators (IPGs) implant site during charging for the Eon IPG and 116 reports of similar symptoms for the Eon Mini IPG, respectively.
Distribution Pattern
Nationwide within the US, and Internationally to Argentina, Australia, Austria, Belgium, Brazil, Canada, Colombia, Cyprus, Czech Republic, Denmark, Finland, France, Germany, Greece, India, Ireland, Isreal, Italy, Japan, Mexico, Netherlands, Puerto Rico, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Turkey, and United Kingdom.
Lot / Code Information
All lots of Eon Mini (Product Code 65-3788)
Other Recalls from Advanced Neuromodulation Systems Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-0025-2013 | Class II | The Eon Mini Implantable Pulse Generator (IPG) ... | Sep 4, 2012 |
| Z-0894-2013 | Class II | Advanced Neuromodulation Systems, Brio DBS Syst... | Mar 28, 2012 |
| Z-1983-2012 | Class II | Eon Mini Neurostimulation (IPG) System (Model 3... | Dec 19, 2011 |
| Z-2280-2012 | Class II | Eon (Model 3716) IPG is a dual channel; 8-conta... | Dec 19, 2011 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic, removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency, Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.